These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 24984040)

  • 1. High HCV treatment uptake in the Swedish HIV/HCV co-infected cohort.
    Stenkvist J; Weiland O; Sönnerborg A; Blaxhult A; Falconer K
    Scand J Infect Dis; 2014 Sep; 46(9):624-32. PubMed ID: 24984040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors associated with guideline-based hepatitis C virus (HCV) treatment initiation in HIV/HCV-coinfected patients: role of comorbidities and physicians' perceptions.
    Winnock M; Bani-Sadr F; Pambrun E; Loko MA; Carrieri P; Neau D; Morlat P; Marchou B; Dabis F; Salmon D;
    HIV Med; 2013 Aug; 14(7):430-6. PubMed ID: 23461846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Considerable under-treatment of chronic HCV infection in HIV patients despite acceptable sustained virological response rates in a real-life setting.
    Reiberger T; Obermeier M; Payer BA; Baumgarten A; Weitner L; Moll A; Christensen S; Köppe S; Kundi M; Rieger A; Peck-Radosavljevic M
    Antivir Ther; 2011; 16(6):815-24. PubMed ID: 21900713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Re-treatment of chronic HCV infection in HIV co-infected patients and predictors of sustained viral response.
    Krastinova E; Bani-Sadr F; Fromentin D; Goujard C; Hessamfar M; Yazdanpanah Y; Pol S; Cacoub P; Perronne C; Carrat F
    J Infect; 2014 May; 68(5):462-6. PubMed ID: 24378283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No reduction of HCV viral load in HIV patients co-infected with HCV genotype 1 during a 30 days course of nitazoxanide monotherapy.
    Laufer N; Abusamra L; Bolcic F; Gun A; Rolón MJ; Pérez H; Krolewiecki A; Salomón H; Quarleri J; Cahn P
    Antiviral Res; 2011 Dec; 92(3):497-9. PubMed ID: 22020160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults.
    Rockstroh JK; Bhagani S; Benhamou Y; Bruno R; Mauss S; Peters L; Puoti M; Soriano V; Tural C;
    HIV Med; 2008 Feb; 9(2):82-8. PubMed ID: 18257771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parenteral drug use as the main barrier to hepatitis C treatment uptake in HIV-infected patients.
    Rivero-Juarez A; Tellez F; Castaño-Carracedo M; Merino D; Espinosa N; Santos J; Macias J; Paniagua-García M; Zapata-Lopez A; Collado A; Gómez-Vidal MA; Perez-Stachowski J; Muñoz-Medina L; Fernandez-Fuertes E; Rivero A;
    HIV Med; 2019 Jul; 20(6):359-367. PubMed ID: 31006980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of insulin resistance on hepatic fibrosis and steatosis in hepatitis C virus (HCV) mono-infected compared with HIV-HCV co-infected patients.
    Halfon P; Pénaranda G; Carrat F; Bedossa P; Bourlière M; Ouzan D; Renou C; Tran A; Rosenthal E; Wartelle C; Delasalle P; Cacoub P
    Aliment Pharmacol Ther; 2009 Jul; 30(1):61-70. PubMed ID: 19292832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to interferon-based therapies in HIV-infected patients with chronic hepatitis C due to genotype 4.
    Soriano V; Núñez M; Sánchez-Conde M; Barreiro P; García-Samaniego J; Martín-Carbonero L; Romero M; González-Lahoz J
    Antivir Ther; 2005; 10(1):167-70. PubMed ID: 15751774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using patient-reported outcomes to improve the management of co-infection with HIV and HCV: the ANRS CO13 HEPAVIH cohort.
    Marcellin F; Roux P; Winnock M; Lions C; Dabis F; Salmon-Ceron D; Loko MA; Spire B; Carrieri MP
    Expert Rev Gastroenterol Hepatol; 2014 May; 8(4):351-8. PubMed ID: 24580042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IP-10 predicts the first phase decline of HCV RNA and overall viral response to therapy in patients co-infected with chronic hepatitis C virus infection and HIV.
    Falconer K; Askarieh G; Weis N; Hellstrand K; Alaeus A; Lagging M
    Scand J Infect Dis; 2010 Dec; 42(11-12):896-901. PubMed ID: 20608766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct-Acting Antiviral Treatment Use Remains Low Among Florida Medicaid Beneficiaries With Chronic Hepatitis C.
    Park H; Song HJ; Jiang X; Henry L; Cook RL; Nelson DR
    Hepatol Commun; 2021 Feb; 5(2):203-216. PubMed ID: 33553969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
    Soriano V; Núñez M; Camino N; Maida I; Barreiro P; Romero M; Martin-Carbonero L; Garcia-Samaniego J; González-Lahoz J
    Antivir Ther; 2004 Aug; 9(4):505-9. PubMed ID: 15456081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained virological response in HIV/HCV co-infected patients treated with pegylated interferon/ribavirin can be predicted from the overall rate of viral load decline over the first 4 weeks of therapy.
    Rivero-Juarez A; Neukam K; Labarga P; Camacho A; Macias J; Barreiro P; Torre-Cisneros J; Pineda JA; Soriano V; Rivero A
    J Infect; 2014 Apr; 68(4):372-7. PubMed ID: 24269677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spontaneous and post-treatment HCV clearance: relationships with health-related quality of life in HIV infection (ANRS-VESPA2 study).
    Marcellin F; Demoulin B; Spire B; Suzan-Monti M; Roux P; Protopopescu C; Sagaon-Teyssier L; Duracinsky M; Dray-Spira R; Carrieri MP;
    Expert Rev Gastroenterol Hepatol; 2015 May; 9(5):701-13. PubMed ID: 25723557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV?
    Rockstroh JK; Peters L; Grint D; Soriano V; Reiss P; Monforte Ad; Beniowski M; Losso MH; Kirk O; Kupfer B; Mocroft A;
    J Hepatol; 2013 Aug; 59(2):213-20. PubMed ID: 23583272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of interferon-based therapy on liver fibrosis progression in HIV/HCV coinfected patients: a retrospective repeated liver biopsy analysis.
    Ingiliz P; Valantin MA; Preziosi P; Finzi L; Pais R; Fedchuk L; Dominguez S; Katlama C; Poynard T; Benhamou Y
    J Hepatol; 2012 Jan; 56(1):49-54. PubMed ID: 21781946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variation in hepatitis C virus treatment uptake between Canadian centres in the era of direct-acting antivirals.
    Nitulescu R; Young J; Saeed S; Cooper C; Cox J; Martel-Laferriere V; Hull M; Walmsley S; Tyndall M; Wong A; Klein MB;
    Int J Drug Policy; 2019 Mar; 65():41-49. PubMed ID: 30594080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C.
    Vispo E; Mena A; Maida I; Blanco F; Cordoba M; Labarga P; Rodriguez-Novoa S; Alvarez E; Jimenez-Nacher I; Soriano V
    J Antimicrob Chemother; 2010 Mar; 65(3):543-7. PubMed ID: 20032006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble CD163 and soluble CD14 plasma levels but not cellular HIV-DNA decrease during successful interferon-free anti-HCV therapy in HIV-1-HCV co-infected patients on effective combined anti-HIV treatment.
    Parisi SG; Andreis S; Mengoli C; Menegotto N; Cavinato S; Scaggiante R; Andreoni M; Palù G; Basso M; Cattelan AM
    Med Microbiol Immunol; 2018 Aug; 207(3-4):183-194. PubMed ID: 29523966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.